Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 13/20 | 0.71 |
| ▸ | KLK1 | P06870 | 1/20 | 0.61 |
| ▸ | LSS | P48449 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | GPR183 | P32249 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5196283 | 0.92 | F10 (0.71) | F10KLK1LSS | |
| SCHEMBL6730422 | 0.89 | F10 (0.74) | F10KLK1 | |
| SCHEMBL6729281 | 0.87 | ATM (0.57) | F10KLK1ATML3MBTL1ALDH1A1 | |
| SCHEMBL6728539 | 0.87 | F10 (0.67) | F10KLK1GPR183HRH4 | |
| SCHEMBL6421218 | 0.83 | F10 (0.51) | F10KLK1LSSATML3MBTL1 | |
| SCHEMBL6424026 | 0.83 | F10 (0.67) | F10KLK1 | |
| SCHEMBL6421003 | 0.82 | F10 (0.56) | F10KLK1ATM | |
| SCHEMBL6730994 | 0.82 | F10 (0.61) | F10KLK1L3MBTL1 | |
| SCHEMBL5193868 | 0.82 | ATM (0.71) | F10LSSATML3MBTL1 | |
| SCHEMBL6737185 | 0.82 | F10 (0.68) | F10KLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1528061-A1 | Heterocyclic derivatives which inhibit factor Xa | AstraZeneca AB (SE) | 2005-05-04 | — | — | EP | disclosed |
| US-20040266759-A1 | Heterocyclic derivatives which inhibit factor Xa | ASTRAZENECA AB | 2004-12-30 | — | — | US | disclosed |
| EP-1082321-B1 | HETEROCYCLIC DERIVATIVES WHICH INHIBIT FACTOR XA | ASTRAZENECA AB (SE) | 2004-11-17 | — | — | EP | disclosed |
| US-6753331-B1 | INDOL-2-YLSULPHONYL-4-(4-(HETEROCYCLE)BENZOYL)PIPERAZINE DERIVATIVES AS ANTICOAGULANTS | ASTRAZENECA AB (SE) | 2004-06-22 | — | — | US | disclosed |
| US-6747023-B1 | INHIBITORS FOR ACTIVATED COAGULATION FACTOR X, COAGULATION SUPPRESSORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-08 | — | — | US | disclosed |
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1104754-A1 | NOVEL SULFONYL DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | F2, CYC1, SULT2A1 | F10 19/4885KLK1 3139/4885LSS 1745/4885 |
| US-20040266759-A1 | Heterocyclic derivatives which inhibit factor Xa | F12, TFPI, F2 | F10 9/4885KLK1 1162/4885LSS 726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.